Kristiina Vuori earned her MD and PhD at University of Oulu, Finland. After completion of internship and residency, she received postdoctoral training at the Institute and was appointed to faculty in 1996. Dr. Vuori was selected as a PEW Scholar in the Biomedical Sciences in 1997. She has been co-Director of the Conrad Prebys Center for Chemical Genomics, housed at Sanford Burnham Prebys, since its inception in 2005. She was appointed Deputy Director of the Institute’s NCI-Designated Cancer Center in 2003, and Director of the Cancer Center in 2006. In 2008, she was appointed Executive Vice President for Scientific Affairs at Sanford Burnham Prebys. She was President of the Institute from 2010 to 2022.
Related Disease
Brain Cancer, Breast Cancer, Cancer, Leukemia/Lymphoma, Lung Cancer, Ovarian Cancer, Prostate Cancer
Dr. Vuori’s research is aimed at unraveling the cell mechanisms of the most life-threatening aspect of cancer, which is cancer metastasis. Metastasis is responsible for nearly all deaths in cancer patients, and understanding of the mechanisms that turn a cancer from a locally growing tumor into highly metastatic cancer cells will provide clues how to prevent this step in cancer progression. All cells in our body stick to one another and to the packaging material, or extracellular matrix, around them. This adhesion is essential for cell survival; if cells become detached from their microenvironment, they will die through a process known as apoptosis. This phenomenon, which is called adhesion dependency of survival, is one of the safeguards that maintain the integrity and normal function of tissues, and prevent cells from becoming cancerous. Normal cells cannot detach from their tissue and establish themselves somewhere else, because they will die on the way. Yet cancer cells somehow get around this requirement; they trespass aggressively into other tissues and metastasize to distant sites in the body without dying. Dr. Vuori’s work is aimed at identifying the molecular mechanisms that in normal cells makes them adhesion-dependent; false action of the very same mechanisms is likely to be the key step in allowing cancer cells to metastasize.
- Feb 1, 2024
New genome mapping tool may uncover secrets for treating blood cancers
Feb 1, 2024The outlook for patients with acute myeloid leukemia (AML), a deadly set of blood cancers that is difficult to treat,…
- Sep 1, 2015
The Mayor of San Diego visits SBP in La Jolla
Sep 1, 2015On Friday, August 28, the Mayor of San Diego, Kevin Faulconer, visited SBP to learn more about how our Institute is
- Jun 24, 2015
A $100 million gift and a new name
Jun 24, 2015We are beyond excited to announce that Sanford-Burnham has received a gift of $100 million from prominent San Diego developer, philanthropist, and
- Apr 21, 2015
Sanford-Burnham presents at AACR April 19-22
Apr 21, 2015The American Association of Cancer Research (AACR) Annual Meeting, held April 18-22 in Philadelphia, will attract approximately 18,000 attendees…
- Dec 16, 2014
National Academy of Inventors names two Sanford-Burnham researchers as charter fellows
Dec 16, 2014 - Dec 16, 2014
National Academy of Inventors names two Sanford-Burnham researchers as Charter Fellows
Dec 16, 2014Two Sanford-Burnham professors have been named Charter Fellows of the National Academy of Inventors (NAI): Erkki Ruoslahti, MD, PhD, distinguished professor and
Select Publications
Showing 3 of 3Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines.
Cipres A, O’Malley DP, Li K, Finlay D, Baran PS, Vuori K
ACS Chem Biol 2010 Feb 19 ;5(2):195-202Critical role for caspase-8 in epidermal growth factor signaling.
Finlay D, Howes A, Vuori K
Cancer Res 2009 Jun 15 ;69(12):5023-9Cell biology. Two lipids that give direction.
Côté JF, Vuori K
Science 2009 Apr 17 ;324(5925):346-7